Observe Medical – Nya Karolinska Sjukhuset initiates new studies to broaden the clinical scope of use for Sippi®
Oslo May 07, 2021 – Observe Medical ASA (OSE: OBSRV), announces that Nya Karolinska Sjukhuset, Sweden, prepares new studies to broaden the clinical scope of use for Sippi® automated, digital urine measurement system, building further on the results from the recent dissertation by Dr Martin Slettengren.
Following the recent dissertation by Dr. Martin Slettengren, ”Evaluation of an automatic urinometer including use of silicone oil to decrease biofilm formation due to proteinuria, hemoglobinuria and bacterial growth”, the team at thorax Intensive Care Unit at Nya Karolinska Sjukhuset, led by Professor Jan van der Linden, has submitted applications for ethical approval for new studies, with the aim of broadening the clinical scope of use for Sippi®. Such studies will support and strengthen the Sippi® commercial opportunity.
“During the COVID-19 pandemics, many patients suffer from acute kidney injury (AKI). AKI is a major clinical challenge in hospitals, often discovered too late, causing severe clinical complications, patient suffering, and costs for the healthcare system. Due to the high data collection frequency supported by proprietary, patented technology, Sippi® is uniquely positioned to identify new diagnostics predictors of AKI,” says Björn Larsson, CEO of Observe Medical.
“The unique technology of the Sippi capacitance based digital urine volume measurement system, allows for identifying new clinical diagnostic parameters, for example for acute kidney injury, based on more detailed urine flow measurements,” comments Professor Jan van der Linden at Nya Karolinska Sjukhuset.
Observe Medical's product Sippi® is the only automated digital urine meter with possibility for wireless data transfer (SippLink™) to the hospital patient data management systems and detects (SippSense®) and hinders (Sippcoat®) biofilm formation, that can lead to urinary infections.
Observe Medical current focus is the clinical rollout of Sippi® in the Nordic region and selected countries in rest of Europe to get systems in clinical use, and to receive customer feedback.
“We are excited about the scientific collaboration with Nya Karolinska Sjukhuset, further strengthening the clinical evidence, value proposition and thus the commercial opportunity for Sippi®,” states Björn Larsson, CEO of Observe Medical ASA.
For further information, please contact:
Observe Medical: Björn Larsson, CEO, +46 76 620 17 25, bjorn.larsson@observemedical.com
About Observe Medical https://observemedical.com/
Observe Medical develops and markets and sells innovative hospital products that contribute to increased patient safety and a more efficient care system. The company’s ambition is to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in combination with targeted M&A. The company’s headquarters is in Oslo, Norway and its operations is based out of Gothenburg, Sweden. Observe Medical has a direct sales organization in the Nordics and a distributor network internationally. Observe Medical's product Sippi® is the only automated digital urine meter with possibility for wireless data transfer to the hospital patient data management systems and hinders biofilm formation that can lead to urinary infections (Sippcoat®). Sippi® is currently being launched with focus on selected markets and hospitals in Nordics and in Europe.